title: FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27.
abstract: Forkhead transcription factors are essential for diverse processes in early embryonic development and organogenesis. As a member of the forkhead family, FOXD1 is required during kidney development and its inactivation results in failure of nephron progenitor cells. However, the role of FOXD1 in carcinogenesis and progression is still limited. Here, we reported that FOXD1 is a potential oncogene in breast cancer. We found that FOXD1 is up-regulated in breast cancer tissues. Depletion of FOXD1 expression decreases the ability of cell proliferation and chemoresistance in MDA-MB-231 cells, whereas overexpression of FOXD1 increases the ability of cell proliferation and chemoresistance in MCF-7 cells. Furthermore, we observed that FOXD1 induces G1 to S phase transition by targeting p27 expression. Our results suggest that FOXD1 may be a potential therapy target for patients with breast cancer.
authors.affiliation: Department of Anesthesiology, The First Affiliated Hospital of the General Hospital of CPLA, Beijing 100048, China.
authors.forename: Yi-Fan
authors.initials: YF
authors.lastname: Zhao
authors.affiliation: Department of Anesthesiology, The First Affiliated Hospital of the General Hospital of CPLA, Beijing 100048, China.
authors.forename: Jing-Yu
authors.initials: JY
authors.lastname: Zhao
authors.affiliation: Department of Anesthesiology, The First Affiliated Hospital of the General Hospital of CPLA, Beijing 100048, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Yue
authors.affiliation: Department of Anesthesiology, The General Hospital of CPLA, Beijing 100853, China.
authors.forename: Ke-Shi
authors.initials: KS
authors.lastname: Hu
authors.affiliation: Department of Anesthesiology, The General Hospital of CPLA, Beijing 100853, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Shen
authors.affiliation: Department of Anesthesiology, The First Affiliated Hospital of the General Hospital of CPLA, Beijing 100048, China. Electronic address: gsgzg304@163.com.
authors.forename: Zheng-Gang
authors.initials: ZG
authors.lastname: Guo
authors.affiliation: Department of Anesthesiology, The First Affiliated Hospital of the General Hospital of CPLA, Beijing 100048, China. Electronic address: lucusebibi@163.com.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Su
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002469:Cell Separation; D002470:Cell Survival; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D034741:RNA, Small Interfering / Q000378:metabolism; D014158:Transcription, Genetic; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; C436291:CDKN1B protein, human; C500800:FOXD1 protein, human; D051858:Forkhead Transcription Factors; D034741:RNA, Small Interfering; D050760:Cyclin-Dependent Kinase Inhibitor p27
keywords: Breast cancer; Cell cycle; Drug resistance; FOXD1; p27